patient series

Validation patient series.

We will test our predictive models by conducting network-driven proof-of-concept patient trials. For this purpose, an active neo-adjuvant systemic therapy program is already in place that recruits over 90 patients per year in the NKI-AVL alone. We shall study fresh tumor material before treatment. We will employ the model to stratify patients based on pathway status and available therapies against MAPK and PI3K pathway components. The tumor will be treated for at least six half-lives and the activation assessed again from the surgical specimen. We will determine if the network state has evolved in the predicted direction. The accuracy of these predictions will serve as an ultimate validation of the model.